Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in KRAS-mutant cancer.
Yang Z, Liang SQ, Saliakoura M, Yang H, Vassella E, Konstantinidou G, Tschan M, Hegedüs B, Zhao L, Gao Y, Xu D, Deng H, Marti TM, Kocher GJ, Wang W, Schmid RA, Peng RW.
Yang Z, et al. Among authors: deng h.
EMBO Mol Med. 2021 Sep 7;13(9):e13193. doi: 10.15252/emmm.202013193. Epub 2021 Aug 8.
EMBO Mol Med. 2021.
PMID: 34369083
Free PMC article.